Rx-to-OTC 開關市場(第 8 版)
市場調查報告書
商品編碼
1073189

Rx-to-OTC 開關市場(第 8 版)

The Market for Rx-to-OTC Switches, 8th Edition

出版日期: | 出版商: Kalorama Information | 英文 195 Pages | 商品交期: 最快1-2個工作天內

價格
簡介目錄

在過去的幾十年裡,超過 700 種藥物已從處方 (Rx) 轉移到 OTC(非處方藥)。美國 Rx-to-OTC 市場已增長到 138 億美元。市場增長的關鍵因素包括專利到期、環境競爭加劇、FDA 與行業合作、品牌重塑、消費者需求和成本控制策略。

本報告分析了美國 Rx-to-OTC 開關(OTC 藥物從處方藥轉換的藥物)市場,分析了市場的基本結構、最新情況、按細分市場劃分的市場規模和 CAGR 趨勢展望(2021-2026),我們將為您提供主要進入者概況和市場份額、主要競爭戰略和競爭形勢等信息。

目錄

第 1 章執行摘要

第二章非處方藥行業

  • OTC(非處方藥)市場概覽
  • 分銷渠道
  • 非處方藥行業:零售市場規模(基於金額)
  • Rx-to-OTC 醫藥市場趨勢
  • Rx-to-OTC 開關:國際趨勢

第 3 章過敏、咳嗽、感冒和鼻竇炎產品

  • 概覽
  • 症狀描述
  • 產品分析
  • 開關產品
  • 最近的轉換活動
  • 處方藥有望獲得 OTC 批准
  • 市場分析
  • 競爭分析

第4章止痛藥

第5章抗感染藥物

第6章胃腸醫學

第7章戒菸產品

第8章其他藥物

第 9 章 Rx-to-OTC 藥品:市場概述

  • 概覽
  • 整個市場分析
  • 美國 Rx-to-OTC 開關市場預測
  • 競爭分析

第10章挑戰與趨勢

  • 國會鼓勵納洛酮開關
  • 消費者健康領域的趨勢
  • 零售策略
  • 併購 (M & A)、合夥企業
  • 同步營銷:處方藥與非處方藥
  • 對處方藥製造商的影響
  • 消費者廣告
  • 專利有效期
  • OTC 產品保險範圍

第 11 章 Rx-to-OTC 市場:主要市場進入公司概況

  • 簡介
  • Bayer AG
  • GlaxoSmithKline
  • Johnson & Johnson
  • Perrigo Company plc
  • Prestige Consumer Healthcare
  • Proctor & Gamble
  • Reckitt Benckiser
  • Sanofi/Chattem
簡介目錄
Product Code: 22-707

More than 700 pharmaceutical products have made the switch from Rx to OTC over the past several decades. The U.S. Rx-to-OTC market has grown into a $13.8 billion market. This has mainly been due to factors such as patent expirations, increasing competitiveness with the pharmaceutical environment, the FDA willingness to work with industry, brand re-invention, consumer demand, and cost containment strategies. The U.S. market for Rx-to-OTC Switches encompasses a wide variety of products that have been determined safe and effective as over-the-counter products, once available only by prescription.

Aging baby boomers, many of which are taking greater interest in their health, have created a growing Rx-to-OTC industry in America. This was reinforced by the pandemic, which presented patients with more selfcare due to lockdowns and mandates. It is anticipated that Rx-to-OTC switch products will continue to grow as interest from both consumers and developers continue to expand. Many of the new products that are on the market may be potential candidates after standing the test of time as a prescription product. Also, the demand for OTC products is not likely to diminish, giving rise to more possibilities in the switched categories. Over one third of American consumers use an OTC medication at least every other day and the numbers are increasing on a regular basis as more products appear on the OTC market.

The current climate of patient-consumer awareness of health issues is continuing to influence the Rx-to-OTC market. Consumers are more prepared to take responsibility for their own health and are willing to purchase medicines over the counter. An increased focus on cost-savings, coupled with the effects of advertising and promotion, result in a higher rate of OTC purchases.

This report, “The Market for Rx-to-OTC Switches, 8th Edition ”, analyses recent switches, products that are near switching. It estimates markets for switched products. Kalorama has examined this market in the past but this report reflects the most up-to-date analysis from Kalorama's last report in 2017.

As part of its coverage, this report contains:

  • Issues and Trends Affecting The Rx-To-OTC Switches Market
  • Leading Participants
  • Information on the OTC industry
  • Overview Of The Over-The-Counter Drug Market
  • International Trends In Rx-To-OTC Switches
  • Markets by Category
  • Allergy, Cough, Cold, and Sinus Products: Recent Switches, Market Size, Forecast, Market Share, Brand vs. Switched Brands vs. Generics (Switched Equivalents), Conditions Information, Overview
  • Analgesics and Other Pain Relievers Recent Switches, Market Size, Forecast, Market Share, Brand vs. Switched Brands vs. Generics (Switched Equivalents), Conditions Information, Overview
  • Anti-Infectives: Recent Switches, Market Size, Forecast, Market Share, Brand vs. Switched Brands vs. Generics (Switched Equivalents), Conditions Information, Overview
  • Gastrointestinal Drugs: Recent Switches, Market Size, Forecast, Market Share, Brand vs. Switched Brands vs. Generics (Switched Equivalents), Conditions Information, Overview
  • Smoking Cessation Products: Recent Switches, Market Size, Forecast, Market Share, Brand vs. Switched Brands vs. Generics (Switched Equivalents), Conditions Information, Overview
  • Other Drugs: Recent Switches, Overview, Size, Forecast, Market Share, Brand vs. Switched Brands vs. Generics (Switched Equivalents)
  • Total Market: Market Size, Forecast, Market Share

Company Coverage

There are several companies that compete heavily in this market and use the Rx-to-OTC switch as a major part of their life-cycle management arsenal. Companies involved in the Rx-to-OTC switched market include brand, generic, and private label manufacturers. Competition will likely continue to be intense in the OTC market.

Consolidation remains a major factor in this market. Most major players have made a significant acquisition or formed a strategic alliance to increase revenues and drive growth. Product innovation, line extensions and strong promotional support are a few of the top strategies for growth in this industry.

Leading competitors offering key brand products are provided in this report. These companies include:

  • Bayer
  • Glaxosmithkline
  • Johnson & Johnson
  • Perrigo Company
  • Prestige Brands
  • Procter & Gamble
  • Reckitt Benckiser
  • Sanofi (Chattem)

Products Discussed In This Report:

  • Carafate
  • Protonix
  • Zofran
  • Nicorette
  • Commit
  • Habitrol
  • Dimetapp
  • Dristan
  • Sudafed
  • Actifed
  • Benadryl
  • Drixoral Plus
  • Nyquil
  • Naphcon A
  • Nasalcrom
  • Mucinex
  • Claritin
  • Zyrtec
  • Aleve
  • Allegra
  • Astepro
  • Lastacaft
  • Aciphex
  • Dexilant
  • Zovirax
  • Xofluza
  • Maxalt
  • Zomig
  • Climara
  • Estraderm
  • Detrol
  • Retin-A
  • Lodine
  • Relafen
  • Zetia
  • Vytorin
  • TriCor
  • Proscar
  • Zithromax
  • Bactroban
  • Chantix
  • Lunesta
  • Ambien
  • Flomax
  • and Scores of Other Brands

The Food and Drug Administration (FDA) is the regulatory authority supervising both the prescription and over-the-counter drug approvals and Rx-to-OTC switches. Through a process, the FDA decides if Rx medications meet the requirements to become OTC available drugs if and when a petition is filed. The FDA evaluates a drug for OTC use upon several factors within a benefit-to-risk comparison. The evaluation includes:

  • Safety-potential overdose or poisoning with possible misuse of the drug and side effects of the drug is determined.
  • Compliance-understanding of OTC label information for proper dosing and administration and correct use without the direction of a physician or pharmacist.
  • Effectiveness-effective treatment of symptoms at doses appropriate for OTC use.
  • Follow up Care-correct diagnosis among consumers for common conditions and follow-up for unresolved symptoms.

Prescription drugs can be introduced for a switch evaluation in one of two ways, either by the manufacturers' submission of additional information to the original drug application for OTC or by a petition by another source for the FDA to evaluate a drug for OTC use.

Submissions to the FDA by a manufacturer are the most common process for an Rx-to-OTC switch. The manufacturer provides information and evidence to support that the drug is safe for self-administration. The submission usually includes data from clinical studies and a preliminary OTC product label, displaying clear instructions for use.

The OTC drug review is a continual assessment of a product by a panel of non-government experts who review a prescription drug's ingredients to determine whether it meets the guidelines for use as a safe drug under OTC marketing regulations. This is a more unconventional process for OTC switches as the manufacturer has not provided data for a formal review of the drug.

Pharmacists Generally Favor Self-Medication

Pharmacists are generally in favor of self-medication and actively promote OTC products. Switches do provide a way for pharmacists to increase profit margins and expand their role as a professional healthcare advisor. In recent surveys pharmacists estimate consumers go on to purchase the pharmacists recommended product at least 85% of the time. It is becoming increasingly important for the health industry to promote the pharmacist-consumer relationship as new OTCs reach the market. However, several barriers to successful relationships have been noted, including:

  • Workload-busy workloads may prevent noticing consumers struggling with product selections.
  • Compensation-lack of compensation for counseling, advice, and recommendations to consumers.
  • Workspace-lack of room to provide adequate consumer counseling.
  • Embarrassment-consumers may not approach pharmacists due to feeling of embarrassment.

The pharmacist's role is becoming enhanced as new products hit the market and the "behind the counter" approach emerges. Pharmacists should be available to assist consumers with several aspects of OTC selection and use. Changes in the industry could enhance the pharmacist's position and increase the level of consumer interaction with pharmacists. A typical counseling session should follow similarly to the figure below.

This report describes these processes and trends in detail, and provides a comprehensive view of the market in 2022.

The information for this report was gathered using both primary and secondary research including comprehensive research of secondary sources such as company literature, government databases, and medical and business journals. Person-to-person, email and telephone interviews were the primary method of gathering information. Over the past decade of Kalorama's research into this market segment, more than 50 direct interviews have been conducted with industry officials, consultants, health providers, company representatives and government personnel. These sources are the primary basis in gathering information specifically relating to revenue and market share data presented in this report. Specific interviews with pharmaceutical company representatives included marketing directors, business development managers, division managers, and product representatives.

All market data pertains to the U.S. market at the manufacturers' level. The base year for data is 2021. Compound annual growth rates (CAGRs) are provided for the 2021-2026, for each industry segment covered.

Table of Contents

Chapter 1: Executive Summary

  • Overview
  • Scope and Methodology
  • Size and Growth of the Market
    • Table 1-1: The U.S. Market for Rx-to-OTC Switches, 2021-2026
  • Issues and Trends Affecting the Rx-to-OTC Switches Market
  • Leading Participants

Chapter 2: The OTC Drug Industry

  • Overview of the Over-the-Counter Drug Market
  • Distribution Channels
    • Table 2-1: Number of Retail Establishments in the United States and Non-Prescription Medicine Availability, 2017
  • Retail Market Value - OTC Drug Industry
    • Figure 2-1: U.S. OTC Retail Sales, 2000-2021
  • Development of the Rx-to-OTC Drug Market
    • Table 2-2: Rx-to-OTC Switches Approved by the FDA, 1976-2021
    • Figure 2-2: Number of New Rx-to-OTC Switches in the United States, per Year 1976-2021
    • Table 2-3: Estimated OTC Sales by Product Category and Percent of Sales Attributed to Rx-to-OTC Switched Ingredients
    • Figure 2-3: Estimated OTC Sales by Product Type and Percent of Sales Attributed to Rx-to-OTC Switched Ingredients (% of total OTC Drug market)
  • U.S. Drug Regulation
  • Expanding Drug Access with Behind the Counter Status
  • Nonprescription Drug Safe Use Regulatory Expansion (NSURE)
  • Physician Uncertainty in Increasing Nonprescription Drug Access
  • Pharmacists Generally Favor Self-Medication
    • Figure 2-4: Typical Pharmacist-Consumer OTC Drug Counseling Session
  • Online Resources for Health Information and Drug Selection
    • Figure 2-5: Internet Uptake has Accelerated During the Pandemic According to the International Telecommunications Union, 2005-2021*
  • Social Media's Influence on Consumer Health Products
  • U.S. Demographics and the Non-Prescription Drug Market
    • Figure 2-6: U.S. Population 2020 and 2030 - > 65 years and < 65 years
  • U.S. Health Spending Indicators
    • Table 2-4: U.S. Healthcare Industry Inflation Rates: Healthcare Industry Consumer Price Index Comparisons, 2015-2020 Data
  • International Trends in Rx-to-OTC Switches
    • Table 2-5: Legal Classification Status of Selected Ingredients by Country (Country Code, Alpha-2) (updated through March 2022)

Chapter 3: Allergy, Cough, Cold, and Sinus Products

  • Overview
  • Antihistamines
  • Decongestants
  • Cough Preparations
  • Ophthalmic Preparations
  • Other Allergy Preparations
  • Mast Cell Stabilizers
  • Intranasal Steroids
  • Description of Conditions
  • Allergic Rhinitis
  • Common Cold
  • Sinusitis
  • Hives
  • Ocular Allergies
    • Figure 3-1: Respiratory Symptoms Impacting Total U.S. Population, Average Annual
  • Product Analysis
  • Switched Products
    • Table 3-1: Allergy, Cough, Cold, Sinus Product Ingredients Transferred from Rx-to-OTC Status
    • Figure 3-2: Allergy, Cough, Cold, Sinus Product Ingredients Transferred from Rx-to-OTC by Year
  • Recent Switch Activity
  • Astepro
  • Pataday Ophthalmic Spray and Solution
  • Lastacaft
  • Nasonex 24hr Allergy
  • Prescription Products with Anticipated OTC Approvals
    • Table 3-2: Rx-to-OTC Product Candidates: Allergy, Cough, Cold, Sinus & Asthma
  • Beconase AQ
  • Clarinex
  • Atrovent Nasal Spray
  • Singulair
  • Ventolin (albuterol) and similar products
  • EpiPen (epinephrine) Autoject
  • Atarax, Vistaril (hydroxyzine)
  • Tessalon (benzonatate)
  • Market Analysis
    • Table 3-3: The U.S. Market for Rx-to-OTC Switches: Allergy/Asthma, Cough, Cold, and Sinus Product Revenues, 2021 and Forecast 2026
    • Figure 3-3: The U.S. Market for Rx-to-OTC Switches: Allergy, Cough, Cold, and Sinus Products, by Percent and Product Type, 2021 and 2026 Estimate
    • Figure 3-4: U.S. Market for Rx-to-OTC Switches: Allergy, Cough, Cold, Sinus, Value Switched Brands vs. Switched Equivalents (Generics), 2010-2021
  • Competitive Analysis
    • Figure 3-5: Leading Suppliers' Shares for U.S. Market for Rx-to-OTC Switches: Allergy, Cough, Cold, and Sinus Products, 2021

Chapter 4: Analgesics and Other Pain Relievers

  • Overview
  • Analgesics
  • Nonsteroidal Anti-inflammatory Drugs
  • Topical Pain Relievers and Other Similar Products
  • Description of Conditions
  • Pain
  • Inflammation
    • Figure 4-1: Pain Symptoms Impacting Total U.S. Population, Average Annual
  • Product Analysis
  • Switched Products
    • Table 4-1: Analgesics, NSAIDs and Other Ingredients Transferred from Rx-to-OTC Status
    • Figure 4-2: Analgesics, NSAIDs and Other Ingredients Transferred from Rx-to-OTC by Year
  • Recent Switch Activity
  • Voltaren Arthritis Pain
  • Prescription Products with Anticipated OTC Approvals
    • Table 4- 2: Rx-to-OTC Product Candidates: Analgesics and Other Pain Relievers
  • Nonsteroidal anti-inflammatory drugs
  • Diflunisal
  • Etodolac
  • Nabumetone
  • Feldene (piroxicam)
  • Migraine Treatments
  • Axert
  • Imitrex
  • Maxalt
  • Zomig
  • Other Migraine Treatments
  • Market Analysis
    • Table 4-3: The U.S. Market for Rx-to-OTC Switches: Analgesic Revenues, 2021 and Forecast 2026
    • Figure 4-3: The U.S. Market for Rx-to-OTC Switches: Analgesic Product by Percent and Product Type, 2021 and 2026 Estimate
    • Figure 4-4: U.S. Market for Rx-to-OTC Switches: Analgesics, Value Switched Brands vs. Switched Equivalents (Generics), 2010-2021
  • Competitive Analysis
    • Figure 4- 5: Leading Suppliers' Shares of the U.S. Market for Rx-to-OTC Switches, Analgesics, 2021

Chapter 5: Anti-Infectives

  • Overview
  • Antibiotics
  • Antifungals
  • Antivirals
  • Antiparasitics
  • Description of Conditions
  • Vaginal Infections
  • Athlete's Foot
  • Jock Itch
  • Ringworm
  • Dandruff
  • Scabies and Pediculosis
  • Pinworm
  • Fungal Nail Infections
    • Figure 5-1: Infection and Fungal Symptoms Impacting Total U.S. Population, Average Annual
  • Product Analysis
  • Switched Products
    • Table 5-1: Anti-infectives Ingredients Transferred from Rx-to-OTC Status
    • Figure 5-2: Anti-infectives Ingredients Transferred from Rx-to-OTC by Year
  • Recent Switch Activity
  • Sklice
  • Prescription Products with Anticipated OTC Approvals
    • Table 5-2: Rx-to-OTC Product Candidates: Anti-Infective Products
  • Antivirals
  • Zovirax
  • Valtrex
  • Denavir
  • Famvir
  • Influenza Antivirals
  • Antibiotics
  • Antifungals
  • Market Analysis
    • Table 5-3: The U.S. Market for Rx-to-OTC Switches, Anti-infective Revenues, 2021 and Forecast 2026
    • Figure 5-3: The U.S. Market for Rx-to-OTC Switches: Anti-infective Product by Percent and Product Type, 2021 and 2026 Estimate
    • Figure 5-4: U.S. Market for Rx-to-OTC Switches: Anti-infective Products, Value Switched Brands vs. Switched Equivalents (Generics), 2010-2021
  • Competitive Analysis
    • Figure 5-5: Leading Suppliers' Shares of the U.S. Market for Rx-to-OTC Switched Anti-infectives, 2021

Chapter 6: Gastrointestinal Drugs

  • Overview
  • Histamine H2 Inhibitors
  • Proton Pump Inhibitors
  • Antidiarrheals
  • Laxatives
  • Others
  • Description of Conditions
  • Nausea
  • Diarrhea
  • Constipation
  • Heartburn
  • Acid reflux
    • Figure 6-1: Gastrointestinal/Digestive Symptoms Impacting Total U.S. Population, Average Annual
  • Product Analysis
  • Switched Products
    • Table 6-1: Gastrointestinal Drug Ingredients Transferred from Rx-to-OTC Status
    • Figure 6-2: Gastrointestinal Drug Ingredients Transferred from Rx-to-OTC by Year
  • Recent Switch Activity
  • Prescription Products with Anticipated OTC Approvals
    • Table 6-2: Rx-to-OTC Product Candidates: Gastrointestinal Products
  • Proton Pump Inhibitors
  • Protonix
  • Aciphex
  • Dexilant
  • Mucosal Protectants
  • Antiemetics
  • Market Analysis
    • Table 6-3: The U.S. Market for Rx-to-OTC Switches, Gastrointestinal Drug Revenues, 2021 and Forecast 2026
    • Figure 6- 3: The U.S. Market for Rx-to-OTC Switches: Gastrointestinal Product by Percent and Product Type, 2021 and 2026 Estimate
    • Figure 6-4: U.S. Market for Rx-to-OTC Switches: Gastrointestinal Products, Value Switched Brands vs. Switched Equivalents (Generics), 2010-2021
  • Competitive Analysis
    • Figure 6-5: Leading Suppliers' Shares of the U.S. Market for Rx-to-OTC Switches, Gastrointestinal Drugs, 2021

Chapter 7: Smoking Cessation Products

  • Overview
  • Description of Conditions
  • Lung Cancer and Tobacco Use
  • Product Analysis
  • Switched Products
    • Table 7-1: Smoking Cessation Product Ingredients Transferred from Rx-to-OTC Status
  • Nicotine Chewing Gum
  • Nicotine Transdermal patch
  • Nicotine Oral lozenge
  • Prescription Products with Anticipated OTC Approvals
    • Table 7-2: Rx-to-OTC Product Candidates: Smoking Cessation Products
  • Nicotrol
  • Chantix
  • Market Analysis
    • Table 7-3: The U.S. Market for Rx-to-OTC Switches, Smoking Cessation Product Revenues, 2021 and Forecast 2026
    • Figure 7-1: The U.S. Market for Rx-to-OTC Switches: Smoking Cessation by Percent and Product Type, 2021 and 2026 Estimate
    • Figure 7- 2: U.S. Market for Rx-to-OTC Switches: Smoking Cessation, Value Switched Brands vs. Switched Equivalents (Generics), 2010-2021
  • Competitive Analysis
    • Figure 7-3 : Leading Suppliers' Shares of the U.S. Market for Rx-to-OTC Switches, Smoking Cessation Drugs, 2021

Chapter 8: Other Drug Classifications

  • Overview
  • Contraceptives
  • Dental Rinses and Fluorides
  • Hair Growth Products
  • Rectal Ointments
  • Sleep Aids
  • Weight Management
  • Urinary Incontinence Products
  • Description of Conditions
  • Pregnancy
    • Table 8-1: U.S. Crude Birth Rate per 1,000 Persons 2000, 2005, 2010, 2015 and 2020
  • Abortion Rates
  • Contraceptive Use
  • Dental caries
  • Hereditary Hair Loss
  • Hemorrhoids
  • Sleeplessness
  • Obesity
  • Urinary Incontinence/Overactive Bladder
  • Conditions with Recent or Possible Future OTC Treatments
  • Benign Prostate Hypertrophy (BPH)
  • Elevated Cholesterol
  • Erectile Dysfunction
  • Menopause and Hormone Replacement
  • Menorrhagia
  • Osteoporosis
  • Product Analysis
  • Switched Ingredients
    • Table 8-2: Miscellaneous Drug Ingredients Transferred from Rx-to-OTC Status by Trade Name, Distributor, and Date of OTC Approval
    • Figure 8-1: Miscellaneous Drug Ingredients Transferred from Rx-to-OTC by Year
  • Contraceptives
  • Dental Rinses and Fluoride
  • Hair Growth
  • Overactive Bladder
  • Rectal Ointments
  • Sleep Aids
  • Weight Management
  • Prescription Products with Anticipated OTC Approvals
    • Table 8-3: Rx-to-OTC Product Candidates: Various Classification of Products
  • Acne Treatments
  • Cholesterol-reducing Drugs (antilipidemics)
  • Blood Products
  • BPH
  • Erectile Dysfunction
  • Hair Loss Treatment
  • Hormone-Replacement Therapies (HRT)
  • Osteoporosis Treatments
  • Opioid Overdose Treatment
  • Overactive Bladder
  • Sleep Aids
  • Market Analysis
  • Current Market Segments
  • Potential Rx-to-OTC Switch Products/Categories
  • Antilipidemics
  • Opioid Overdose Treatment
  • Sexual Dysfunction
  • BPH Treatments
  • Hormone Replacement Therapy and Osteoporosis Treatments
  • Competitive Analysis

Chapter 9: Total Rx-to-OTC Drug Market Summary

  • Overview
  • Total Market Analysis
    • Table 9-1: The U.S. Market for Rx-to-OTC Switches, 2021-2026
    • Figure 9-1: The U.S. Market for Rx-to-OTC Switches, 2021 and 2026 Forecast
  • Switch Forecast in the United States
    • Table 9-2: Potential Rx-to-OTC Switches for U.S. Markets
    • Figure 9-2: The U.S. Market for Rx-to-OTC Switches, Distribution of Revenues by Product Category, 2021 and 2026 Forecast
  • Competitive Analysis
    • Table 9-3: Top 5 Rx-to-OTC Switch Suppliers Significant Segments of Participation, 2021
    • Figure 9-3: Leading Suppliers Market Share in the U.S. Market for Rx-to-OTC Switches, 2021

Chapter 10: Issues and Trends

  • Naloxone Switch Encouraged by Congress
  • Trends in Consumer Health Divisions
  • Retail Strategies
  • Mergers, Acquisitions and Partnerships
  • Simultaneous Marketing - Prescription vs. OTC
  • Impact on the Prescription Drug Manufacturer
  • Direct-to-Consumer Advertising
  • Patent Expiration
  • Insurance Coverage for OTC Products

Chapter 11: Profiles for Major Rx-to-OTC Participants

  • Introduction
  • Bayer AG
    • Table 11-1: Bayer AG Corporate Summary
  • Company Overview
  • Switch Products
  • GlaxoSmithKline
    • Table 11-2: GlaxoSmithKline Corporate Summary
  • Company Overview
  • Switched Products
  • Johnson & Johnson
    • Table 11-3: Johnson & Johnson Corporate Summary
  • Company Overview
  • Switched Products
  • Perrigo Company plc
    • Table 11-4: Perrigo Corporate Summary
  • Company Overview
  • Switched Products
  • Prestige Consumer Healthcare
    • Table 11-5: Prestige Consumer Healthcare Corporate Summary
  • Company Overview
  • Proctor & Gamble
    • Table 11-6: Proctor & Gamble Corporate Summary
  • Company Overview
  • Reckitt Benckiser
    • Table 11-7: Reckitt Benckiser Corporate Summary
  • Company Overview
  • Sanofi/Chattem
    • Table 11-8: Sanofi Corporate Summary
  • Company Overview